Viewing Protocol Section

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
Viewing Protocol Section

Thank You for evaluating our software.

Clinical Trials

To give you an idea of how we make custom software. We have taken all of the Clinical Trials Information from our Federal Government(https://clinicaltrials.gov/).

The JSON File Structure of the files is as follows: Full Study -> Study => Sections => Modules. You are currently viewing a Protocol Section and its Modules.

We give the table structure here to give you an idea of what you are looking at. We put the explanation to the left and the data to the right.

A Protocol Section has the following Modules.

1. Identification Module

2. Status Module

3. Sponsor Collaborators Module

4. Oversight Module

5. Description Module

6. Conditions Module

7. Design Module

8. Arms Interventions Module

9. Outcomes Module

10. Eligibility Module

11. Contacts Locations Module

12. References Module

13. IPD Sharing Statement Module

Viewing Protocol Section

Study NCT06287944
Ignite Creation Date: 2024-05-06 @ 8:10 PM
Last Modification Date: 2024-10-26 @ 3:22 PM
Study NCT ID: NCT06287944
Protocol Section: NCT06287944
Start Identification Module Data
Expand Identification Module Data
Brief Title: 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
Official Title: Phase I Study of Escalating Doses of 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody Added to the Conditioning Regimen of Fludarabine Melphalan and Organ Sparing Total Marrow and Lymphoid Irradiation TMLI as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With High-Risk Acute Myeloid Leukemia Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
Acronym: None
Organization: City of Hope Medical Center
Organization Class: OTHER
Organization Study ID: 23694
Secondary IDs
Secondary ID Type Domain Link
P30CA033572 NIH City of Hope Medical Center httpsreporternihgovquickSearchP30CA033572
NCI-2024-01131 REGISTRY None None
23694 OTHER None None
Start Status Module Data
Status Verified Date: 2024-08
Overall Status: NOT_YET_RECRUITING
Study First Submit Date:
Study First Submit QC Date:
Last Update Submit Date:
Status:
Start Sponsor Collaborators Module Data
Investigator:
Lead Sponsor: City of Hope Medical Center
Lead Sponsor Class: OTHER
Lead Sponsor: City of Hope Medical Center
Start Oversight Module Data 480097
Description Module: 483597
Study Last Update Post Date Type(Status Module):
Attachment: Upload